Clinical characteristics of HBsAg+ and HBsAg− FL patients
| . | HBsAg+ FL (%) . | HBsAg− FL (%) . | P value* . |
|---|---|---|---|
| Number of patients | 32 | 103 | |
| Age (y)‡ | |||
| >60 | 4 (13%) | 32 (31%) | .038† |
| ≤60 | 28 (87%) | 71 (69%) | |
| Sex‡ | |||
| Female | 14 (44%) | 44 (43%) | .918 |
| Male | 18 (56%) | 59 (57%) | |
| Performance status‡ | |||
| 0-1 | 30 (94%) | 96 (94%) | .939 |
| 2-4 | 2 (6%) | 6 (6%) | |
| Elevated LDH‡ | |||
| Yes | 13 (43%) | 19 (20%) | .012† |
| No | 17 (57%) | 75 (80%) | |
| Stage‡ | |||
| I-II | 5 (17%) | 23 (23%) | .445 |
| III-IV | 25 (83%) | 76 (77%) | |
| FLIPI score‡ | |||
| 0-1 | 5 (19%) | 15 (17%) | .991 |
| 2 | 7 (26%) | 24 (27%) | |
| 3-5 | 15 (55%) | 49 (56%) | |
| M7-FLIPI score‡ | |||
| High risk | 4 (17%) | 17 (22%) | .628 |
| Low risk | 19 (83%) | 60 (78%) | |
| PRIMA-PI‡ | |||
| High risk | 2 (13%) | 22 (30%) | .158 |
| Intermediate risk | 3 (19%) | 5 (7%) | |
| Low risk | 11 (69%) | 47 (64%) | |
| Grade‡ | |||
| 1-2 | 6 (19%) | 59 (61%) | <.001† |
| 3A | 15 (48%) | 27 (27%) | |
| 3B | 5 (16%) | 3 (3%) | |
| 3 (mixed 3A and 3B) | 3 (10%) | 6 (6%) | |
| 3A/B combined DLBCL | 2 (7%) | 5 (5%) | |
| POD24 (R-CHOP)‡ | |||
| Yes | 10 (48%) | 13 (23%) | .037† |
| No | 11 (52%) | 43 (77%) | |
| . | HBsAg+ FL (%) . | HBsAg− FL (%) . | P value* . |
|---|---|---|---|
| Number of patients | 32 | 103 | |
| Age (y)‡ | |||
| >60 | 4 (13%) | 32 (31%) | .038† |
| ≤60 | 28 (87%) | 71 (69%) | |
| Sex‡ | |||
| Female | 14 (44%) | 44 (43%) | .918 |
| Male | 18 (56%) | 59 (57%) | |
| Performance status‡ | |||
| 0-1 | 30 (94%) | 96 (94%) | .939 |
| 2-4 | 2 (6%) | 6 (6%) | |
| Elevated LDH‡ | |||
| Yes | 13 (43%) | 19 (20%) | .012† |
| No | 17 (57%) | 75 (80%) | |
| Stage‡ | |||
| I-II | 5 (17%) | 23 (23%) | .445 |
| III-IV | 25 (83%) | 76 (77%) | |
| FLIPI score‡ | |||
| 0-1 | 5 (19%) | 15 (17%) | .991 |
| 2 | 7 (26%) | 24 (27%) | |
| 3-5 | 15 (55%) | 49 (56%) | |
| M7-FLIPI score‡ | |||
| High risk | 4 (17%) | 17 (22%) | .628 |
| Low risk | 19 (83%) | 60 (78%) | |
| PRIMA-PI‡ | |||
| High risk | 2 (13%) | 22 (30%) | .158 |
| Intermediate risk | 3 (19%) | 5 (7%) | |
| Low risk | 11 (69%) | 47 (64%) | |
| Grade‡ | |||
| 1-2 | 6 (19%) | 59 (61%) | <.001† |
| 3A | 15 (48%) | 27 (27%) | |
| 3B | 5 (16%) | 3 (3%) | |
| 3 (mixed 3A and 3B) | 3 (10%) | 6 (6%) | |
| 3A/B combined DLBCL | 2 (7%) | 5 (5%) | |
| POD24 (R-CHOP)‡ | |||
| Yes | 10 (48%) | 13 (23%) | .037† |
| No | 11 (52%) | 43 (77%) | |